Amgen Inc. (BMV:AMGN)

Market Cap	3.23T
Revenue (ttm)	659.79B
Net Income (ttm)	128.49B
Shares Out	n/a
EPS (ttm)	237.23
PE Ratio	25.15
Forward PE	15.92
Dividend	183.45 (2.96%)
Ex-Dividend Date	Nov 21, 2025

Volume	10
Average Volume	552
Open	6,200.01
Previous Close	6,312.70
Day's Range	6,200.01 - 6,200.01
52-Week Range	5,023.00 - 6,680.00
Beta	0.46
RSI	62.58
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD